In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …

Pirtobrutinib (JaypircaTM), a highly selective, non-covalent, reversible Bruton's tyrosine
kinase (BTK) inhibitor, is being developed by Eli Lilly and Company (Lilly) for the treatment …

Simple Summary Non-covalent Bruton's tyrosine kinase inhibitors (ncBTKi) are being
investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia …

Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly
develops in the lymph node (LN) and creates a protective and immunosuppressive niche …

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its
indolent clinical course, therapy refractoriness and disease progression still represent an …

Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the
treatment of multiple B-cell malignancies and are being evaluated for autoimmune and …

Bruton's tyrosine kinase (BTK) plays a key role in the B-cell receptor (BCR) signaling
pathway and confers anti-apoptotic and proliferative properties to malignant B-cells in …

In January 2023, the FDA granted accelerated approval to pirtobrutinib for the treatment of
adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines …

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …